<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2023-12-3-41-48</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1537</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАЦЕВТИЧЕСКАЯ ТЕХНОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACEUTICAL TECHNOLOGY</subject></subj-group></article-categories><title-group><article-title>Изучение биофармацевтических свойств новой мукоадгезивной лекарственной формы для терапии дегенеративных заболеваний глаз</article-title><trans-title-group xml:lang="en"><trans-title>Biopharmaceutical Properties of New Mucoadhesive Dosage Form for Eye Degenerative Diseases Treatment</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7649-9616</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Анурова</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Anurova</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, г. Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>8/2, Trubetskaya str., Mosсow, 119991</p></bio><email xlink:type="simple">amn25@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8695-0346</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бахрушина</surname><given-names>Е. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Bakhrushina</surname><given-names>E. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, г. Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>8/2, Trubetskaya str., Mosсow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1590-7268</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лапик</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lapik</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, г. Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>8/2, Trubetskaya str., Mosсow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0707-4574</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тураева</surname><given-names>А. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Turaeva</surname><given-names>A. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, г. Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>8/2, Trubetskaya str., Mosсow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4307-8791</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демина</surname><given-names>Н. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Demina</surname><given-names>N. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, г. Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>8/2, Trubetskaya str., Mosсow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9933-1808</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сысуев</surname><given-names>Б. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Sysuev</surname><given-names>B. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, г. Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>8/2, Trubetskaya str., Mosсow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7242-2988</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Краснюк</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Krasnyuk</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, г. Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>8/2, Trubetskaya str., Mosсow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И. М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)</institution></aff><aff xml:lang="en"><institution>I. M. Sechenov First MSMU of the Ministry of Health of the Russian Federation (Sechenov University)</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>29</day><month>08</month><year>2023</year></pub-date><volume>12</volume><issue>3</issue><fpage>41</fpage><lpage>48</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Анурова М.Н., Бахрушина Е.О., Лапик И.В., Тураева А.Р., Демина Н.Б., Сысуев Б.Б., Краснюк И.И., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Анурова М.Н., Бахрушина Е.О., Лапик И.В., Тураева А.Р., Демина Н.Б., Сысуев Б.Б., Краснюк И.И.</copyright-holder><copyright-holder xml:lang="en">Anurova M.N., Bakhrushina E.O., Lapik I.V., Turaeva A.R., Demina N.B., Sysuev B.B., Krasnyuk I.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1537">https://www.pharmjournal.ru/jour/article/view/1537</self-uri><abstract><sec><title>Введение</title><p>Введение. Дегенеративные заболевания сетчатки, в том числе глаукома, являются основной причиной потери зрения у взрослого населения. Разработка и усовершенствование медикаментозного лечения данной группы заболеваний представляет собой актуальную проблему.</p></sec><sec><title>Цель</title><p>Цель. Изучение новой лекарственной формы метилэтилпиридинола в виде офтальмологического геля.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Объекты исследования – образцы глазных гелей, содержащих метилэтилпиридинол, для которых изучали мукоадгезию комбинацией методов in vitro / ex vivo. Биодеградацию и кинетику высвобождения действующего вещества из лекарственной формы изучали на тестере растворения в среде искусственной слезной жидкости. Срок годности лекарственной формы устанавливали в соответствии с программой изучения стабильности. Определение местнораздражающего действия проводили методом конъюнктивальной пробы у 10 кроликов породы шиншилла массой 3,6–4,1 кг.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. В работе представлены результаты изучения биофармацевтических характеристик ранее разработанного офтальмологического геля метилэтилпиридинола на основе неионного полимера – гидроксиэтилцеллюлозы марки Natrosol™ 250 HHX. Проведено сравнительное изучение мукоадгезии методом потока in vitro / ex vivo образцов офтальмологического геля в диапазоне концентрации гидроксиэтилцеллюлозы в геле 1–1,5 %. Лучшими адгезивными характеристиками обладал образец с содержанием полимера 1,5 %, который имел минимальную скорость потока: in vitro 2,7 · 106 м/с и ex vivo 2,3 · 106 м/с. Изучены кинетика растворения и визуальная биодеградация образца после теста «Растворение», которая говорит о пролонгированном высвобождении метилэтилпиридинола из геля. Показана стабильность разработанной лекарственной формы в долгосрочных и стрессовых условиях. Выполнена оценка местнораздражающего действия методом конъюнктивальной пробы.</p></sec><sec><title>Заключение</title><p>Заключение. Были определены основные биофармацевтические характеристики разработанного офтальмологического геля метилэтилпиридинола и показано, что он может быть использован как система доставки для лечения дегенеративных заболеваний сетчатки, так как обладает выраженными биоадгезивными свойствами, пролонгированным высвобождением. По результатам определения срока годности готовой лекарственной формы сделан вывод, что он составляет 2 года. Проведены стрессовые исследования геля метилэтилпиридинола. Разработанный офтальмологический гель не обладает местнораздражающим действием.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Degenerative retinal diseases, including glaucoma, are the main cause of vision loss in the adult population. The development and improvement of drug treatment of this group of diseases is an urgent problem.</p></sec><sec><title>Aim</title><p>Aim. Study of a new dosage form of methylethylpyridinol in the form of an ophthalmic gel.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The objects of the study were samples of eye gels containing methylethylpyridinol, for which mucoadhesion was studied by a combination of in vitro / ex vivo methods. Biodegradation and release kinetics of the active substance from the dosage form were studied using a dissolution tester in an artificial tear fluid medium. The shelf life of the dosage form was established in accordance with the stability study program. Determination of the local irritative action was carried out by conjunctival test in 10 rabbits of chinchilla breed weighing 3,6–4,1 kg.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. The article presents the results of the study of biopharmaceutical characteristics of the previously developed ophthalmic gel of methylpyridinol based on a nonionic polymer – hydroxyethylcellulose brand Natrosol™ 250 HHX. A comparative study of mucoadhesion by in vitro / ex vivo flow of ophthalmic gel samples in the range of hydroxyethylcellulose concentration in the gel of 1–1.5 % was performed. The sample with 1.5 % polymer content had the best adhesive characteristics because it had a minimum flow rate: in vitro 2.7 · 106 m/s and ex vivo 2.3 · 106 m/s. Dissolution kinetics and visual biodegradation of the sample after "Dissolution" test were studied, which indicates prolonged release of methyl ethyl pyridinol from the gel. The stability of the developed dosage form under long-term and stress conditions was shown. The local irritating effect was estimated by the conjunctival test.</p></sec><sec><title>Conclusion</title><p>Conclusion. The main biopharmaceutical characteristics of the developed ophthalmic gel methylpyridinol were determined and it was shown that it can be used as a delivery system for the treatment of degenerative retinal diseases because it possesses marked bioadhesive properties and prolonged release. The shelf life of the dosage form was determined, which was 2 years. Stress studies of methylethylpyridinol gel were carried out. The developed ophthalmic gel has no local irritating effect.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>метилэтилпиридинол</kwd><kwd>эмоксипин</kwd><kwd>дегенеративные заболевания сетчатки</kwd><kwd>глазные гели</kwd><kwd>мукоадгезия</kwd><kwd>местнораздражающее действие</kwd></kwd-group><kwd-group xml:lang="en"><kwd>methylethylpyridinol</kwd><kwd>emoxipine</kwd><kwd>degenerative retinal diseases</kwd><kwd>eye gels</kwd><kwd>mucoadhesion</kwd><kwd>local irritant effect</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена при финансовой поддержке Минобрнауки РФ (договор № 02.G25.31.0001) в рамках реализации Постановления Правительства РФ от 09.04.2010 г. № 218.</funding-statement><funding-statement xml:lang="en">The work was supported financially by the Ministry of Education and Science of the Russian Federation (contract no. 02.G25.31.0001) as part of the implementation of Decree of the Government of the Russian Federation No. 218 dated April 9, 2010.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">He S., Stankowska D. L., Ellis D. Z., Krishnamoorthy R. R., Yorio T. Targets of Neuroprotection in Glaucoma. Journal of Ocular Pharmacology and Therapeutics. 2018;34(1–2):85–106. DOI: 10.1089/jop.2017.0041.</mixed-citation><mixed-citation xml:lang="en">He S., Stankowska D. L., Ellis D. Z., Krishnamoorthy R. R., Yorio T. Targets of Neuroprotection in Glaucoma. Journal of Ocular Pharmacology and Therapeutics. 2018;34(1–2):85–106. DOI: 10.1089/jop.2017.0041.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Jeon S., Oh I. H. Regeneration of the retina: toward stem cell therapy for degenerative retinal diseases. BMB Reports. 2015;48(4):193–199. DOI: 10.5483/bmbrep.2015.48.4.276.</mixed-citation><mixed-citation xml:lang="en">Jeon S., Oh I. H. Regeneration of the retina: toward stem cell therapy for degenerative retinal diseases. BMB Reports. 2015;48(4):193–199. DOI: 10.5483/bmbrep.2015.48.4.276.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang N., Wang J., Li Y., Jiang B. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. Scientific Report. 2021;11(1):13762. DOI: 10.1038/s41598-021-92971-w.</mixed-citation><mixed-citation xml:lang="en">Zhang N., Wang J., Li Y., Jiang B. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. Scientific Report. 2021;11(1):13762. DOI: 10.1038/s41598-021-92971-w.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kisa A., Kisa S., Renzaho A. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. The Lancet Global Health. 2021;9(2):e144–e160. DOI: 10.1016/S2214-109X(20)30489-7.</mixed-citation><mixed-citation xml:lang="en">Kisa A., Kisa S., Renzaho A. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. The Lancet Global Health. 2021;9(2):e144–e160. DOI: 10.1016/S2214-109X(20)30489-7.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Нероев В. В., Зайцева О. В., Михайлова Л. А. Заболеваемость диабетической ретинопатией в Российской Федерации по данным Федеральной статистики. Российский офтальмологический журнал. 2018;11(2):5–9. DOI: 10.21516/2072-0076-2018-11-2-5-9.</mixed-citation><mixed-citation xml:lang="en">Neroev V. V., Zaytseva O. V., Mikhailova L. A. Incidence of diabetic retinopathy in the russian federation according to federal statistics. Russian Ophthalmological Journal. 2018;11(2):5–9. (In Russ.) DOI: 10.21516/2072-0076-2018-11-2-5-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Паштаев Н. П., Иванова Т. Г., Горбунова Н. Ю., Артемьева Т. Ф., Маркова А. А., ред. Комплексное лечение пациентов глаукомной оптической нейропатией: практическое руководство для врачей. Чебоксары: ГОУ «Институт усовершенствования врачей»; 2008. 24 с.</mixed-citation><mixed-citation xml:lang="en">Pashtaev N. P., Ivanona T. G., Gorbunova N. Yu., Artem’eva T. F., Markova А. А., editors. Comprehensive treatment of patients with glaucoma optic neuropathy: a practical guide for physicians. Cheboksary: GOU «Institute for the Improvement of Physicians»; 2008. 24 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Егоров Е. А., Гветадзе А. А. Новые возможности применения метилэтилпиридинола в офтальмологической практике. РМЖ «Клиническая офтальмология». 2018;19(4):190–192. DOI: 10.21689/2311-7729-2018-18-4-190-192.</mixed-citation><mixed-citation xml:lang="en">Egorov E. A., Gvetadze A. A. New possibilities of using methylaethylpiridinolum in ophthalmological practice. RMJ "Clinical ophthalmology". 2018;4:190–192. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Obukhova L. K., Nakaidze N. Sh., Serebryany A. M., Smirnov L. D., Akifiev A. P. Experimental analysis of the mechanisms of ageing in Drosophila melanogaster. Experimental gerontology. 1979;14(6):335–341. DOI: 10.1016/0531-5565(79)90046-9.</mixed-citation><mixed-citation xml:lang="en">Obukhova L. K., Nakaidze N. Sh., Serebryany A. M., Smirnov L. D., Akifiev A. P. Experimental analysis of the mechanisms of ageing in Drosophila melanogaster. Experimental gerontology. 1979;14(6):335–341. DOI: 10.1016/0531-5565(79)90046-9.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Даутова З. А., Митрофанова Н. В. Применение препарата Эмоксипин в комплексном лечении глаукомы. Практическая медицина. 2016;2:150–156.</mixed-citation><mixed-citation xml:lang="en">Dutova Z. А., Mitrofanova N. V. The use of Emoxipin in the complex treatment of glaucoma. Practical medicine. 2016;2:150–156. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ченцова Е. В., Алексеева И. Б. Куликов А. Н. Диагностика и лечение первичной открытоугольной глаукомы. Федеральные клинические рекомендации. М.: ФГБУ «МНИИ ГБ им. Гельмгольца» Минздрава России; 2012. 32 с.</mixed-citation><mixed-citation xml:lang="en">Chentsova E. V., Alexeeva I. B. Kulikov A. N. Diagnostics and treatment of primary open angle glaucoma. Federal clinical guidelines. Moscow: FGBU "MRI GB named after Helmholtz" of the Ministry of Health and Social Development of Russia; 2012. 32 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Stavitskaya T. V., Egorov E. A.,Voitova S. P. Study of Separate and Combination application Timoptic XL. Ophthalmic research. 1999;1(31):45.</mixed-citation><mixed-citation xml:lang="en">Stavitskaya T. V., Egorov E. A.,Voitova S. P. Study of Separate and Combination application Timoptic XL. Ophthalmic research. 1999;1(31):45.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ставицкая Т. В. Изучение фармакокинетики прямых нейропротекторов, применяемых у больных глаукомой. Клиническая офтальмология. 2003;2(4):61–63.</mixed-citation><mixed-citation xml:lang="en">Stavitskaya T. V. Study of the pharmacokinetics of direct neuroprotectors used in patients with glaucoma. Russian Journal of Clinical Ophthalmology. 2003;2(4):61–63. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ставицкая Т. В. Нейропротекторное действие некоторых гипотензивных препаратов. Глаз. 2004;3(37):31–37.</mixed-citation><mixed-citation xml:lang="en">Stavitskaya T. V. Neuroprotective effect of some antihypertensive drugs. The Eye. 2004;3(37):31–37. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kim Y. H., Lin M. C., Radke C. J. Central-to-peripheral corneal edema during wear of embedded-component contact lenses. Contact Lens and Anterior Eye. 2022;45(1):101443. DOI: 10.1016/j.clae.2021.101443.</mixed-citation><mixed-citation xml:lang="en">Kim Y. H., Lin M. C., Radke C. J. Central-to-peripheral corneal edema during wear of embedded-component contact lenses. Contact Lens and Anterior Eye. 2022;45(1):101443. DOI: 10.1016/j.clae.2021.101443.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y. M., Xie P. The Safety of Orthokeratology-A Systematic Review. Eye contact lens. 2016;42(1):35–42. DOI: 10.1097/ICL.0000000000000219.</mixed-citation><mixed-citation xml:lang="en">Liu Y. M., Xie P. The Safety of Orthokeratology-A Systematic Review. Eye contact lens. 2016;42(1):35–42. DOI: 10.1097/ICL.0000000000000219.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cassano R., Di Gioia M. L., Trombino S. Gel-Based Materials for Ophthalmic Drug Delivery. Gels. 2021;7(3):130. DOI: 10.3390/gels7030130.</mixed-citation><mixed-citation xml:lang="en">Cassano R., Di Gioia M. L., Trombino S. Gel-Based Materials for Ophthalmic Drug Delivery. Gels. 2021;7(3):130. DOI: 10.3390/gels7030130.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Jeon S., OhI. H. Regeneration of the Retina: Toward Stem Cell Therapy for Degenerative Retinal Diseases. BMB Reports. 2015;48(4):193–199. DOI: 10.5483/bmbrep.2015.48.4.276.</mixed-citation><mixed-citation xml:lang="en">Jeon S., OhI. H. Regeneration of the Retina: Toward Stem Cell Therapy for Degenerative Retinal Diseases. BMB Reports. 2015;48(4):193–199. DOI: 10.5483/bmbrep.2015.48.4.276.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sakamoto K., Mori A., Ishii K., Nakahara T. Selective Neuronal Cell Death in Retinal Degenerative Diseases Nihon Yakurigaku. Zasshi. 2018;152(2):58–63. DOI: 10.1254/fpj.152.58.</mixed-citation><mixed-citation xml:lang="en">Sakamoto K., Mori A., Ishii K., Nakahara T. Selective Neuronal Cell Death in Retinal Degenerative Diseases Nihon Yakurigaku. Zasshi. 2018;152(2):58–63. DOI: 10.1254/fpj.152.58.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Salinger C. L., Gaynes B. I., Rajpal R. K. Innovations in Topical Ocular Corticosteroid Therapy for the Management of Postoperative Ocular Inflammation and Pain. The American journal of managed care. 2019;25(12 Suppl):S215–S226.</mixed-citation><mixed-citation xml:lang="en">Salinger C. L., Gaynes B. I., Rajpal R. K. Innovations in Topical Ocular Corticosteroid Therapy for the Management of Postoperative Ocular Inflammation and Pain. The American journal of managed care. 2019;25(12 Suppl):S215–S226.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Анурова М. Н., Лапик И. В., Бахрушина Е. О., Кречетов С. П., Краснюк И. И. Технологические аспекты фармацевтической разработки офтальмологического геля эмоксипина. Вестник Воронежского государственного университета. Серия: Химия. Биология. Фармация. 2017;4:117–123.</mixed-citation><mixed-citation xml:lang="en">Anurova M. N., Lapik I. V., Bakhrushina E. O., Krechetov S. P., Krasnyuk I. I. Technological aspects of emoxipine ophthalmic gel formulation development. Proceedings of Voronezh State University. Series: Chemistry. Biology. Pharmacy. 2017;4:117–123. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Анурова М. Н., Бахрушина Е. О., Лапик И. В., Шитова А. С., Краснюк И. И. Определение осмотической активности офтальмологических гелей. Разработка и регистрация лекарственных средств. 2018;3(24):36–40.</mixed-citation><mixed-citation xml:lang="en">Anurova M. N., Bakhrushina E. O., Lapik I. V., Shitova A. S., Krasnyuk I. I. The study of the osmotic activity of ophtalmic gels. Drug development &amp; registration. 2018;(3):30–34. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Анурова М. Н., Бахрушина Е. О., Лапик И. В., Кречетов С. П. Современные аспекты создания глазных лекарственных форм: Определение реологических оптимумов офтальмологических гелей. Разработка и регистрация лекарственных средств. 2017;4(21):46–52.</mixed-citation><mixed-citation xml:lang="en">Anurova M. N., Bakhrushina E. O., Lapik I. V., Krechetov S. P. The determination of the rheological optimum of ophthalmic gels. Modern aspects of the ophthalmic dosage forms development. Drug development &amp; registration. 2017;(4):64–70. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Tripathi R., Balne P. K., Sinha N. R., Martin L. M., Kamil S., Landreneau J. R., Gupta S., Rodier J. T., Sinha P. R., Hesemann N. P., Hofmann A. C., Fink M. K., Chaurasia S. S., Mohan R. R. A Novel Topical Ophthalmic Formulation to Mitigate Acute Mustard Gas Keratopathy In Vivo: A Pilot Study. Translational vision science &amp; technology. 2020;9(12):6. DOI: 10.1167/tvst.9.12.6.</mixed-citation><mixed-citation xml:lang="en">Tripathi R., Balne P. K., Sinha N. R., Martin L. M., Kamil S., Landreneau J. R., Gupta S., Rodier J. T., Sinha P. R., Hesemann N. P., Hofmann A. C., Fink M. K., Chaurasia S. S., Mohan R. R. A Novel Topical Ophthalmic Formulation to Mitigate Acute Mustard Gas Keratopathy In Vivo: A Pilot Study. Translational vision science &amp; technology. 2020;9(12):6. DOI: 10.1167/tvst.9.12.6.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Glickman R. D., Onorato M., Campos M. M., O'Boyle M. P., Singh R. K., Zarembinski T. I., Binette F., Nasonkin I. O. Intraocular Injection of HyStem Hydrogel Is Tolerated Well in the Rabbit Eye. Journal ocular pharmacology &amp; theraupetics. 2021;37(1):60–71. DOI: 10.1089/jop.2020.0042.</mixed-citation><mixed-citation xml:lang="en">Glickman R. D., Onorato M., Campos M. M., O'Boyle M. P., Singh R. K., Zarembinski T. I., Binette F., Nasonkin I. O. Intraocular Injection of HyStem Hydrogel Is Tolerated Well in the Rabbit Eye. Journal ocular pharmacology &amp; theraupetics. 2021;37(1):60–71. DOI: 10.1089/jop.2020.0042.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Bakhrushina E., Anurova M., Demina N., Kashperko A., Rastopchina O., Bardakov A., Krasnyuk I. Comparative Study of the Mucoadhesive Properties of Polymers for Pharmaceutical Use. Open access Macedonian journal of medical sciences. 2020;8(A):639–645. DOI: 10.3889/oamjms.2020.4930.</mixed-citation><mixed-citation xml:lang="en">Bakhrushina E., Anurova M., Demina N., Kashperko A., Rastopchina O., Bardakov A., Krasnyuk I. Comparative Study of the Mucoadhesive Properties of Polymers for Pharmaceutical Use. Open access Macedonian journal of medical sciences. 2020;8(A):639–645. DOI: 10.3889/oamjms.2020.4930.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Bao Q., Newman B., Wang Y., Choi S., Burgess D. J. In vitro and ex vivo correlation of drug release from ophthalmic ointments. Journal of Controlled Release. 2018;276:93–101. DOI: 10.1016/j.jconrel.2018.03.003.</mixed-citation><mixed-citation xml:lang="en">Bao Q., Newman B., Wang Y., Choi S., Burgess D. J. In vitro and ex vivo correlation of drug release from ophthalmic ointments. Journal of Controlled Release. 2018;276:93–101. DOI: 10.1016/j.jconrel.2018.03.003.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Краснюк И. И., Демина Н. Б., Анурова М. Н., Соловьева Н. Л. Биофармация или основы фармацевтической разработки, производства и обоснования дизайна лекарственных форм. М.: ГЭОТАР-Медиа; 2019. 184 с.</mixed-citation><mixed-citation xml:lang="en">Krasnyuk I. I., Demina N. B., Anurova M. N, Solovyova N. L. Biopharmacy or the basics of pharmaceutical development, production and justification of the design of dosage forms. Moscow: GEOTAR-Media; 2019. 184 p. (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
